Drug intelligence / Profile preview

ifosfamide + vindesine

Development stage: Unknown
Lead developer: NuGen Medical Devices
Modality: Small Molecules
Administration: Intravenous

Overview

Ifosfamide + vindesine is a chemotherapy combination used primarily for the treatment of advanced non-small cell lung cancer (NSCLC). This combination has also been studied in metastatic renal cell cancer. Ifosfamide is an alkylating agent chemically related to nitrogen mustards, while vindesine is a vinca alkaloid. When used together, they demonstrate cytotoxic activity against cancer cells through different mechanisms. In clinical studies, this combination has often been used with cisplatin (forming the VIP regimen), showing response rates of approximately 39-48% in NSCLC with manageable toxicity.

Targets

DNA

Beyond the preview

Go deeper on ifosfamide + vindesine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ifosfamide + vindesine.

Explore the full profile